Category: Smith & Nephew
Shares of Smith & Nephew are up today on solid 3rd-quarter results, including 6% growth for its U.S. hip implant business.
Smith & Nephew says the U.S. Patent & Trademark Office confirmed the validity of a patent at issue in an ongoing infringement battle with Arthrex.
Here's a look at some of the top regulatory stories for medical device companies this week: Medtronic announces leadership roster for post-Covidien merger; Allergan raises outlook; says Valeant offer undervalues company; EuroZone anti-trust regulators to rule next month on $43B Covidien buy; Steris to buy UK's Synergy Health, tax savings eyed; Bioventus bolsters bone healing lineup
Smith & Nephew spinout Bioventus acquires the OsteoAMP bone tissue line from Advanced Biologics.
Bioventus said it acquired the OsteoAMP product line from Advanced Biologics for an undisclosed amount.
OsteoAMP is a tissue-based product used to promote natural bone growth and healing in the spine, according to a press release.
Smith & Nephew's HP802-247 spraoy-on leg ulcer treatment fails a Phase III clinical trial, despite promising early studies.
Here's a look at some of the top legal news stories for medical device companies this week: Ex-ArthroCare CEO Baker draws 20 years; Smith & Nephew settles whistleblower lawsuit for $8M; Secant Medical escapes pelvic mesh cases; Bellwether trial kicks off for DePuy's Pinnacle hip implant; J&J, Boston Scientific, others can't shake Philly pelvic mesh mass tort
, Boston Scientific
, C.R. Bard
, Dept. of Justice (DOJ)
, DePuy Synthes
, Endo Health
, Ethicon Inc.
, Johnson & Johnson
, Secant Medical
, Smith & Nephew
, U.S. Veterans Affairs Dept. (VA)
, American Medical Systems Holdings Inc.
Smith & Nephew agrees to the $8 million settlement of a whistleblower's lawsuit alleging it passed off devices manufactured overseas as made in the U.S.